| Metronomic Therapy in Patients With Metastatic Melanoma (NCT01542255) | Dartmouth-Hitchcock Medical Center | 2010-06-01 |
| Ipilimumab + Temozolomide in Metastatic Melanoma (NCT01119508) | M.D. Anderson Cancer Center | 2010-05-01 |
| Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M... (NCT01118091) | National Cancer Institute (NCI) | 2010-04-01 |
| QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma (NCT01029873) | Altor BioScience | 2010-02-01 |
| Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma (NCT01014351) | SCRI Development Innovations, LLC | 2010-02-01 |
| A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg) (NCT01082887) | Nantes University Hospital | 2010-01-01 |
| Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma (NCT01216436) | Duke University | 2010-01-01 |
| Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat (NCT00925132) | University of Iowa | 2009-12-01 |
| Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma (NCT00747825) | Molecular Insight Pharmaceuticals, Inc. | 2009-12-01 |
| Dose Escalation Study of MLN4924 in Adults With Melanoma (NCT01011530) | Millennium Pharmaceuticals, Inc. | 2009-12-01 |
| Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma (NCT01005745) | H. Lee Moffitt Cancer Center and Research Institute | 2009-10-20 |
| Study of Gene Modified Immune Cells in Patients With Advanced Melanoma (NCT00910650) | Jonsson Comprehensive Cancer Center | 2009-10-13 |
| A Study to Assess PV-10 Chemoablation of Cancer of the Liver (NCT00986661) | Provectus Biopharmaceuticals, Inc. | 2009-10-01 |
| Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma (NCT00984464) | Oncolytics Biotech | 2009-09-01 |
| A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma (NCT00804908) | AbbVie (prior sponsor, Abbott) | 2009-02-01 |
| Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma (NCT01005472) | Jonsson Comprehensive Cancer Center | 2008-12-01 |
| Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma (NCT00881049) | Peking University | 2008-12-01 |
| A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies (NCT00730639) | Bristol-Myers Squibb | 2008-10-30 |
| Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma (NCT00414765) | Novartis Pharmaceuticals | 2008-09-03 |
| Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients (NCT01134250) | Philogen S.p.A. | 2008-08-06 |
| Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy (NCT00604136) | Hadassah Medical Organization | 2008-07-01 |
| Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma (NCT01055522) | Philogen S.p.A. | 2008-06-01 |
| A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma (NCT00724841) | Gemin X | 2008-06-01 |
| Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer (NCT00670748) | National Cancer Institute (NCI) | 2008-05-29 |
| Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma (NCT00665470) | National Cancer Institute (NCI) | 2008-04-01 |
| A Novel Treatment for Metastatic Melanoma (NCT00758797) | Northwestern University | 2008-04-01 |
| Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma (NCT00679289) | Ludwig Institute for Cancer Research | 2008-03-28 |
| Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma (NCT00609011) | Myrexis Inc. | 2008-03-01 |
| A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma (NCT00627419) | Infinity Pharmaceuticals, Inc. | 2008-02-01 |
| Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma (NCT00612222) | National Cancer Institute (NCI) | 2008-01-01 |
| RAD001 Plus Bevacizumab in Metastatic Melanoma (NCT00591734) | SCRI Development Innovations, LLC | 2008-01-01 |
| Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells (NCT00672542) | Scott Pruitt | 2008-01-01 |
| A Phase I/II Study of Dasatinib and Dacarbazine (NCT00597038) | H. Lee Moffitt Cancer Center and Research Institute | 2007-11-01 |
| Rituximab in Metastatic Melanoma (NCT01032122) | Medical University of Vienna | 2007-10-01 |
| Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma (NCT01503827) | Melanoma and Skin Cancer Trials Limited | 2007-10-01 |
| Clinical Trial of Sutent to Treat Metastatic Melanoma (NCT00631618) | California Pacific Medical Center Research Institute | 2007-09-01 |
| A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients (NCT00526617) | AbbVie | 2007-08-01 |
| Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients (NCT00553618) | University of Louisville | 2007-08-01 |
| Study of ADI-PEG 20 in Patients With Advanced Melanoma (NCT00520299) | Ludwig Institute for Cancer Research | 2007-07-01 |
| Long-term Data Collection for Subjects in MDX-010 Studies (NCT00928031) | Bristol-Myers Squibb | 2007-06-01 |
| Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma (NCT00399113) | Pain Therapeutics | 2007-05-01 |
| Intratumoral Injection Of Alpha-Gal Glycosphingolipids (NCT00668512) | University of Massachusetts, Worcester | 2007-03-01 |
| A Study of Tasisulam in Treating Participants With Malignant Melanoma (NCT00383292) | Eli Lilly and Company | 2006-11-01 |
| A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma (NCT00395070) | Vical | 2006-10-01 |
| Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy (NCT00571116) | University of California, Irvine | 2006-09-01 |
| Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer (NCT00328861) | National Cancer Institute (NCI) | 2006-05-01 |
| Melanoma Biomarker Study (NCT00348088) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2006-05-01 |
| A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma (NCT00304525) | Novartis Pharmaceuticals | 2006-04-01 |
| RFT-5-dgA in Patients With Metastatic Melanoma (NCT00314093) | University of Texas Southwestern Medical Center | 2006-04-01 |
| Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma (NCT00314106) | National Cancer Institute (NCI) | 2006-04-01 |
| Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer (NCT00304460) | National Cancer Institute (NCI) | 2006-03-13 |
| A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma (NCT00402662) | Yale University | 2006-02-01 |
| Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients (NCT00287131) | Sheba Medical Center | 2006-01-01 |
| The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2 (NCT00279058) | Hadassah Medical Organization | 2005-12-01 |
| Taxoprexin Treatment for Advanced Skin Melanoma (NCT00249262) | American Regent, Inc. | 2005-10-01 |
| Taxoprexin® Treatment for Advanced Eye Melanoma (NCT00244816) | American Regent, Inc. | 2005-10-01 |
| A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma (NCT00121680) | Eisai Inc. | 2005-07-01 |
| A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma (NCT00223899) | Vical | 2005-07-01 |
| Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma (NCT00139360) | Haukeland University Hospital | 2005-05-01 |
| Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma (NCT00301067) | Northwestern University | 2005-01-30 |
| Taxotere/Temodar/Cisplatin Study in Melanoma Patients (NCT00527761) | M.D. Anderson Cancer Center | 2004-08-01 |
| Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma (NCT00256282) | John P. Fruehauf | 2003-04-01 |
| Multiepitope Peptide Vaccination in Melanoma (NCT00153569) | Charite University, Berlin, Germany | 2003-03-01 |
| Dendritic Cells (DC) Vaccine for Metastatic Melanoma (NCT01042366) | John Kirkwood | 2002-10-01 |
| Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma (NCT00203879) | University of Chicago | 2002-02-01 |
| Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma (NCT00226473) | Dermatologic Cooperative Oncology Group | 2001-09-01 |
| Phase II Trial of Allovectin-7® for Metastatic Melanoma (NCT00044356) | Vical | 2001-02-01 |
| Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells (NCT00948480) | Hoag Memorial Hospital Presbyterian | 2000-10-01 |
| The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma (NCT00626860) | Beth Israel Deaconess Medical Center | 2000-07-01 |
| A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma (NCT00733798) | TransMolecular | |